The Prime Minister, Justin Trudeau, has announced an investment of up to $173 million through the Strategic Innovation Fund (SIF) in Quebec City-based Medicago to support Canada’s response to COVID-19 and future preparedness.
The project (total value $428 million) will advance Medicago’s virus-like particle vaccine, developed through clinical trials. It will also establish a large-scale vaccine and antibody production facility to increase Canada’s domestic biomanufacturing capacity.
So far the Government of Canada has signed agreements with Medicago, Sanofi, GlaxoSmithKline, Novavax, Johnson & Johnson, Pfizer and Moderna. At this time, there are three vaccine candidates currently under review and many others in clinical trials and in development.
Check out previous updates on COVID-19 vaccines:
Word of the Day:Preparedness: state of being ready or prepared